inclusion criteria: 1. subjects or their legal representatives have signed the informed consent form(icf); agree not to participate in other clinical studies within 30 days after the last administration from the first administration of the study drug. 2. subjects are aged ≥ 18 and ≤ 75; 3. meet the diagnostic criteria for 2019-ncov pneumonia (v5.0); 4. sofa score: 1 \~ 13 points. 5. a retreated patient or the relapsed patient meets any of the following criteria: * have fever again or aggravated clinical symptoms; ② 2019ncovrna in the throat swabs converts from negative to positive; ③ the clinical symptoms don't improve or 2019ncovrna continues to be positive; ④ the chest ct shows pneumonia or fibrosis progression. clinical stratification: 1. mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in ct, but positive 2019-ncov in throat swabs or gargle. 2. ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in ct. 3. severe type: meeting any of the following criteria: (1) respiratory distress, rr≥30 times/min; (2) finger oxygen saturation ≤93% in rest state; (3) arterial partial pressure of oxygen (pao2)/concentration of oxygen inhalation (fio2)≤300mmhg (1mmhg=0.133kpa). 4. critical type: meeting any of the following criteria:(1)respiratory failure occurs and mechanical ventilation is required;(2)patients go into shock;(3)icu is needed for other organ failure.

inclusion criteria: 1. subjects or their legal representatives have signed the informed consent form(icf); agree not to participate in other clinical studies within 30 days after the last administration from the first administration of the study drug. 2. subjects are aged ≥ 18 and ≤ 75; 3. meet the diagnostic criteria for 2019-ncov pneumonia (v5.0); 4. sofa score: 1 \~ 13 points. 5. a retreated patient or the relapsed patient meets any of the following criteria: * have fever again or aggravated clinical symptoms; ② 2019ncovrna in the throat swabs converts from negative to positive; ③ the clinical symptoms don't improve or 2019ncovrna continues to be positive; ④ the chest ct shows pneumonia or fibrosis progression. clinical stratification: 1. mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in ct, but positive 2019-ncov in throat swabs or gargle. 2. ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in ct. 3. severe type: meeting any of the following criteria: (1) respiratory distress, rr≥30 times/min; (2) finger oxygen saturation ≤93% in rest state; (3) arterial partial pressure of oxygen (pao2)/concentration of oxygen inhalation (fio2)≤300mmhg (1mmhg=0.133kpa). 4. critical type: meeting any of the following criteria:(1)respiratory failure occurs and mechanical ventilation is required;(2)patients go into shock;(3)icu is needed for other organ failure.

inclusion criteria: subjects or their legal representatives have signed the informed consent form(icf); agree not to participate in other clinical studies within 30 days after the last administration from the first administration of the study drug. subjects are aged ≥ 18 and ≤ 75; meet the diagnostic criteria for 2019-ncov pneumonia (v5.0); sofa score: 1 ~ 13 points. a retreated patient or the relapsed patient meets any of the following criteria: have fever again or aggravated clinical symptoms; ② 2019ncovrna in the throat swabs converts from negative to positive; ③ the clinical symptoms don't improve or 2019ncovrna continues to be positive; ④ the chest ct shows pneumonia or fibrosis progression. clinical stratification: mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in ct, but positive 2019-ncov in throat swabs or gargle. ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in ct. severe type: meeting any of the following criteria: (1) respiratory distress, rr≥30 times/min; (2) finger oxygen saturation ≤93% in rest state; (3) arterial partial pressure of oxygen (pao2)/concentration of oxygen inhalation (fio2)≤300mmhg (1mmhg=0.133kpa). 4. critical type: meeting any of the following criteria:(1)respiratory failure occurs and mechanical ventilation is required;(2)patients go into shock;(3)icu is needed for other organ failure.

inclusion criteria: subjects or their legal representatives have signed the informed consent form(icf); agree not to participate in other clinical studies within 30 days after the last administration from the first administration of the study drug. subjects are aged ≥ 18 and ≤ 75; meet the diagnostic criteria for 2019-ncov pneumonia (v5.0); sofa score: 1 ~ 13 points. a retreated patient or the relapsed patient meets any of the following criteria: have fever again or aggravated clinical symptoms; ② 2019ncovrna in the throat swabs converts from negative to positive; ③ the clinical symptoms don't improve or 2019ncovrna continues to be positive; ④ the chest ct shows pneumonia or fibrosis progression. clinical stratification: mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in ct, but positive 2019-ncov in throat swabs or gargle. ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in ct. severe type: meeting any of the following criteria: (1) respiratory distress, rr≥30 times/min; (2) finger oxygen saturation ≤93% in rest state; (3) arterial partial pressure of oxygen (pao2)/concentration of oxygen inhalation (fio2)≤300mmhg (1mmhg=0.133kpa). 4. critical type: meeting any of the following criteria:(1)respiratory failure occurs and mechanical ventilation is required;(2)patients go into shock;(3)icu is needed for other organ failure.

inclusion criteria: 1. subjects or their legal representatives have signed the informed consent form(icf); agree not to participate in other clinical studies within 30 days after the last administration from the first administration of the study drug. 2. subjects are aged ≥ 18 and ≤ 75; 3. meet the diagnostic criteria for 2019-ncov pneumonia (v5.0); 4. sofa score: 1 ~ 13 points. 5. a retreated patient or the relapsed patient meets any of the following criteria: - have fever again or aggravated clinical symptoms; ② 2019ncovrna in the throat swabs converts from negative to positive; ③ the clinical symptoms don't improve or 2019ncovrna continues to be positive; ④ the chest ct shows pneumonia or fibrosis progression. clinical stratification: 1. mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in ct, but positive 2019-ncov in throat swabs or gargle. 2. ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in ct. 3. severe type: meeting any of the following criteria: (1) respiratory distress, rr≥30 times/min; (2) finger oxygen saturation ≤93% in rest state; (3) arterial partial pressure of oxygen (pao2)/concentration of oxygen inhalation (fio2)≤300mmhg (1mmhg=0.133kpa). 4. critical type: meeting any of the following criteria:(1)respiratory failure occurs and mechanical ventilation is required;(2)patients go into shock;(3)icu is needed for other organ failure.

inclusion criteria: 1. subjects or their legal representatives have signed the informed consent form(icf); agree not to participate in other clinical studies within 30 days after the last administration from the first administration of the study drug. 2. subjects are aged ≥ 18 and ≤ 75; 3. meet the diagnostic criteria for 2019-ncov pneumonia (v5.0); 4. sofa score: 1 ~ 13 points. 5. a retreated patient or the relapsed patient meets any of the following criteria: - have fever again or aggravated clinical symptoms; ② 2019ncovrna in the throat swabs converts from negative to positive; ③ the clinical symptoms don't improve or 2019ncovrna continues to be positive; ④ the chest ct shows pneumonia or fibrosis progression. clinical stratification: 1. mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in ct, but positive 2019-ncov in throat swabs or gargle. 2. ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in ct. 3. severe type: meeting any of the following criteria: (1) respiratory distress, rr≥30 times/min; (2) finger oxygen saturation ≤93% in rest state; (3) arterial partial pressure of oxygen (pao2)/concentration of oxygen inhalation (fio2)≤300mmhg (1mmhg=0.133kpa). 4. critical type: meeting any of the following criteria:(1)respiratory failure occurs and mechanical ventilation is required;(2)patients go into shock;(3)icu is needed for other organ failure.